98%
921
2 minutes
20
Background And Objective: Magnetic resonance imaging (MRI)/ultrasound-guided high-intensity focused ultrasound (HIFU) ablates prostate cancer with promising cancer control and minimal impact on sexual or urinary function. However, recurrence remains a concern. This study identifies factors associated with recurrence and treatment failure to optimize patient selection.
Methods: Men who underwent robotic HIFU (FocalOne) at University of California San Francisco (2021-2023) and had a 1-yr post-HIFU MRI-fusion biopsy were included. The primary outcomes were biopsy-proven in-field and overall recurrence. The secondary outcomes included treatment failure (salvage whole-gland treatment with surgery or radiation, or development of metastases) and changes in urinary/sexual function. Cox proportional hazards and multivariable logistic regression were used for an analysis.
Key Findings And Limitations: Among 135 men with a follow-up biopsy at 12 mo, pre-HIFU Gleason grade ≥3 (≥GG3; hazard ratio [HR] 3.11; 95% confidence interval [CI] 1.30-7.47) and a high genomic risk score (HR 2.87; 95% CI 1.18-6.99) were associated with in-field biopsy-proven recurrence. Overall biopsy-proven recurrence was linked to ≥GG3 (HR 2.62; 95% CI 1.03-6.67) and prostate-specific antigen (PSA) >10 versus <6 ng/ml (HR 5.64; 95% CI 1.82-17.48). The rates of treatment failure requiring salvage whole-gland treatment or metastasis was 4% at 1 yr and 16% overall, with a median (interquartile range) time to treatment failure of 16 (13-18) mo. Urinary and sexual function remained unchanged; no Clavien-Dindo grade >2 complications, urethral stricture, or urethra-rectal fistula were recorded.
Conclusions And Clinical Implications: Pre-HIFU ≥GG3 disease, a high genomic risk score, and elevated PSA correlate with local recurrence. These findings emphasize the importance of careful patient selection, as HIFU can effectively control cancer with minimal urinary or sexual side effects in suitable patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.euf.2025.06.007 | DOI Listing |
Minerva Pediatr (Torino)
September 2025
Pediatric Respiratory Unit, Department of Clinical and Experimental Medicine, San Marco Hospital, University of Catania, Catania, Italy.
Allergen immunotherapy (AIT) is the only treatment capable of modifying the natural history of allergic diseases by promoting immune tolerance. Initially developed for respiratory allergies, AIT has expanded to include food allergies, particularly through oral immunotherapy (OIT). This review explores the historical evolution, current applications, and future directions of AIT in pediatric patients.
View Article and Find Full Text PDFLangenbecks Arch Surg
September 2025
Department of Surgery HBP Unit, Simone Veil Hospital, University of Reims Champagne-Ardenne, Troyes, France.
Introduction: Pancreatic adenocarcinomas (PDAC) have a poor prognosis, with a 5-year relative Survival rate of 11.5%. Only 20% of patients are initially eligible for resection, and 50% of patients presented with metastatic disease, currently only candidates' palliative treatment.
View Article and Find Full Text PDFAnn Surg Oncol
September 2025
Cancer Center, Renmin Hospital of Wuhan University, Wuhan, China.
Background: The optimal number of examined lymph nodes (ELN) for accurate staging and prognosis for esophageal cancer patients receiving neoadjuvant therapy remains controversial. This study aimed to evaluate the impact of ELN count on pathologic staging and survival outcomes and to develop a predictive model for lymph node positivity in this patient population.
Methods: Data were extracted from the Surveillance, Epidemiology, and End Results (SEER) database and a multicenter cohort.
Int J Surg
September 2025
Department of Cardiovascular Surgery, The Affiliated Hospital, Southwest Medical University, Metabolic Vascular Diseases Key Laboratory of Sichuan Province, Key Laboratory of Cardiovascular Remodeling and Dysfunction, Luzhou, Sichuan, PR China.
Objective: This meta-analysis aimed to compare the perioperative safety and efficacy of transcatheter aortic valve replacement (TAVR) versus surgical aortic valve replacement (SAVR) in bicuspid aortic valve (BAV) stenosis.
Methods: We systematically analyzed studies from PubMed, Cochrane Library, Embase, and CNKI comparing TAVR and SAVR in BAV stenosis. Outcomes included postoperative mortality, complications, all-cause survival, and freedom from stroke.
Cardiol Rev
September 2025
Departments of Cardiology and Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY.
Sepsis remains a leading cause of critical illness and mortality worldwide, driven by a dysregulated host response to infection and often complicated by persistent tachycardia and cardiovascular dysfunction. Increasing evidence implicates excessive sympathetic activation as a contributor to sepsis-related hemodynamic instability and myocardial injury, prompting growing interest in the use of β-adrenergic blockade as a therapeutic adjunct. This review synthesizes current data on the safety and efficacy of short-acting, cardioselective β-blockers (BBs), particularly esmolol and landiolol, in septic shock.
View Article and Find Full Text PDF